Arbutus Biopharma Corporation (ABUS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Short Interest
Short interest: 10.49% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
- Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
- Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
- Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
- Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
- Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
- ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
- Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Arbutus Biopharma Corporation.
Full ABUS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.